Pentoxifylline Improves Pulmonary Gas Exchange: RESULTS

1 May
2011

RESULTS

The patients with COPD ranged from moderately impaired (FEV, = 50 percent predicted, Deo = 17 ml/ min/mm Hg) to severely impaired (FEV\<50 percent predicted, Dco<12 ml/min/mm Hg). There were no significant differences between the treatment and control groups with respect to MEFV parameters, residual volume, heart rate, oxygen saturation, or diffusing capacity (Table 1). All of the healthy subjects had normal results of pulmonary function tests (FEV, = 99.2 ±4.7 percent of predicted, resting Deo = 28.4 ±2.8 ml/min/mm Hg, mean±SE).

All of the patients were using theophylline, most also used an albuterol spray, and two used oxygen at night. Theophylline levels remained within accepted therapeutic levels throughout the program and did not vary systematically in the COPD treatment group with the addition of pentoxifylline.
kamagra soft tablets

FIGURE 1. Treadmill walk time in the treated group (left hand panel) before pentoxifylline therapy and during the 12th week of treatment. Treadmill walk time in the control group (right hand panel) before and after the 12-week period. Lines represent individual subjects; closed circles illustrate averaged data± SE.

Treadmill walk time (Fig 1) in the COPD treatment group increased from 17.7 ±2.9 minutes to 23.2 ±2.9 minutes (p<0.01) by the end of treatment. Then it slowly returned toward baseline during the six weeks following pentoxifylline treatment. In contrast, the control groups stress test walk time did not change appreciably from the beginning to the end of the protocol (16.4 ±3.5 minutes to 17.5±4.0 minutes, respectively). Walking peak heart rate did not change in either group (Table 2). As illustrated in Figure 2, resting Deo, however, increased from a baseline level of 8.1 ±2.0 ml/min/mm Hg to a maximum of 10.6 ±2.6 ml/min/mm Hg, p<0.02). Then Deo values returned toward baseline during the six weeks following termi­nation of treatment. This parameter did not change from the start to the end of week 12 in either the COPD control group (9.8 ±2.3 and 9.3 ±2.5 ml/min/ mm Hg) or the healthy group (28.4 ± 2.8 and 28.1 ±2.5 ml/min/mm Hg).
Viagra Super Active

Table 2—Exercise Barometers for the COPD Groups

HR Rest, HR Exercise,

SoxiO,

Soxi02

Subject

BPM

BPM

Rest

Exercise

Treated Croup

Baseline

1

103

167

96

94

2

84

101

94

92

3

88

112

94

91

4

112

149

91

86

5

89

97

93

87

6

94

101

89

89

12th week of

medication

1

99

164

96

94

2

81

92

98

94

3

84

112

93

92

4

115

151

93

89

5

88

94

92

89

6

96

110

Control Croup

92

90

Baseline

1

90

109

93

93

2

95

136

94

89

3

88

114

94

92

4

86

160

94

94

5

79

90

95

95

6

88

111

88

80

12th week

retest

1

90

104

93

90

2

95

131

94

90

3

86

116

93

93

4

86

145

94

90

5

83

98

86

90

6

95

116

93

81

 

top